← Russell 3000 cross-section

VCEL Vericel Corp

Trailing twelve months to 2026-06-30 · as filed 2026-07-30, not restated
Healthcare

Scale

Market cap
$2.2bn
Revenue TTM
$306m
Net income TTM
$24m
Free cash flow
$62m
Composite score
49.3
Sector rank
#1602

Valuation

P / E
89.2
EV / EBITDA
64.1
EV / sales
6.5
FCF yield
2.86%
Earnings yield vs 10-yr
-3.61pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
7.9%
EBITDA margin
10.2%
ROE
6.5%
ROIC
8.8%
Revenue growth
22.9%

Insider activity, last 90 days

Net open-market
$-3.64m
Buyers
0
Sellers
6

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

In the last five years through 2025, MACI sales volumes from the first through the fourth quarter on average represented 21% (20%-22% range), 23% (22%-24% range), 22% (21%-24% range) and 34% (33%-34% range) respectively, of total annual volumes. Gross Profit Gross profit increased for the three and six months ended June 30, 2026, compared to the same periods in 2025, primarily driven by MACI and Epicel revenue growth combined with our primarily fixed manufacturing cost structure, which consists mainly of labor and facility costs. …Vericel Corp, 10-Q, period ended 2026-06-30, filed 2026-07-30

Read the full passage →